FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783019558> ?p ?o ?g. }

• W2783019558 abstract "Abstract The aims of this randomized, double‐blind, three‐arm, single‐dose study were to demonstrate pharmacokinetic (PK) equivalence of the adalimumab biosimilar M923 (hereafter referred to as “M923”) to each of 2 reference products, and to assess M923's safety and immunogenicity. Primary PK endpoints were maximum observed concentration ( C max ), area under the curve (AUC) from time 0 extrapolated to infinity (AUC 0‐inf ), and AUC from time 0 to 336 hours (AUC 0‐336 ). Secondary endpoints included safety and immunogenicity assessments. Healthy subjects were randomized 1:1:1 to receive a 40‐mg dose of M923 (n = 107); adalimumab US Humira (n = 105), hereafter referred to as “US Humira”; or adalimumab EU Humira (n = 103), hereafter referred to as “EU Humira.” PK equivalence was demonstrated for all primary PK endpoints . Geometric least squares means ratios (GMRs) for C max , AUC 0‐inf , and AUC 0‐336 were 99.4, 100.9, and 100.5, respectively, between the M923 and EU Humira arms and 102.6, 104.2, and 102.9 between the M923 and US Humira arms. The 90% confidence intervals of the GMRs for all PK endpoints were within prespecified confidence bounds of 80%‐125%. Adverse event rates were similar across the M923 (47.7%), US Humira (50.9%), and EU Humira (53.3%) arms and were generally mild (73.7%) or moderate (22.0%). The proportion of subjects with a confirmed antidrug antibody (ADA) response was similar across study arms. This study demonstrated bioequivalent PK among M923, US Humira, and EU Humira and demonstrated that the PK parameters were consistent with similar safety and tolerability profile and ADA response rates." @default.
• W2783019558 created "2018-01-26" @default.
• W2783019558 creator A5000443245 @default.
• W2783019558 creator A5005801217 @default.
• W2783019558 creator A5011238310 @default.
• W2783019558 creator A5014240433 @default.
• W2783019558 creator A5015885477 @default.
• W2783019558 creator A5019745578 @default.
• W2783019558 creator A5034410165 @default.
• W2783019558 creator A5036975640 @default.
• W2783019558 creator A5041895022 @default.
• W2783019558 creator A5043557126 @default.
• W2783019558 creator A5046991927 @default.
• W2783019558 creator A5052060673 @default.
• W2783019558 creator A5059427438 @default.
• W2783019558 creator A5062186840 @default.
• W2783019558 creator A5083717158 @default.
• W2783019558 creator A5084360444 @default.
• W2783019558 creator A5090611203 @default.
• W2783019558 date "2018-01-08" @default.
• W2783019558 modified "2023-09-28" @default.
• W2783019558 title "Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects" @default.
• W2783019558 cites W1176283365 @default.
• W2783019558 cites W1596457615 @default.
• W2783019558 cites W1909377197 @default.
• W2783019558 cites W1968416967 @default.
• W2783019558 cites W1990305566 @default.
• W2783019558 cites W1991810959 @default.
• W2783019558 cites W2019167664 @default.
• W2783019558 cites W2023048488 @default.
• W2783019558 cites W2063627867 @default.
• W2783019558 cites W2088736174 @default.
• W2783019558 cites W2105968451 @default.
• W2783019558 cites W2108987697 @default.
• W2783019558 cites W2119046820 @default.
• W2783019558 cites W2129301243 @default.
• W2783019558 cites W2133541603 @default.
• W2783019558 cites W2140163728 @default.
• W2783019558 cites W2290515360 @default.
• W2783019558 cites W2417110244 @default.
• W2783019558 cites W2480028188 @default.
• W2783019558 cites W2582177931 @default.
• W2783019558 cites W2599639640 @default.
• W2783019558 doi "https://doi.org/10.1002/prp2.380" @default.
• W2783019558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5817835" @default.
• W2783019558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29417761" @default.
• W2783019558 hasPublicationYear "2018" @default.
• W2783019558 type Work @default.
• W2783019558 sameAs 2783019558 @default.
• W2783019558 citedByCount "14" @default.
• W2783019558 countsByYear W27830195582018 @default.
• W2783019558 countsByYear W27830195582019 @default.
• W2783019558 countsByYear W27830195582020 @default.
• W2783019558 countsByYear W27830195582021 @default.
• W2783019558 countsByYear W27830195582022 @default.
• W2783019558 crossrefType "journal-article" @default.
• W2783019558 hasAuthorship W2783019558A5000443245 @default.
• W2783019558 hasAuthorship W2783019558A5005801217 @default.
• W2783019558 hasAuthorship W2783019558A5011238310 @default.
• W2783019558 hasAuthorship W2783019558A5014240433 @default.
• W2783019558 hasAuthorship W2783019558A5015885477 @default.
• W2783019558 hasAuthorship W2783019558A5019745578 @default.
• W2783019558 hasAuthorship W2783019558A5034410165 @default.
• W2783019558 hasAuthorship W2783019558A5036975640 @default.
• W2783019558 hasAuthorship W2783019558A5041895022 @default.
• W2783019558 hasAuthorship W2783019558A5043557126 @default.
• W2783019558 hasAuthorship W2783019558A5046991927 @default.
• W2783019558 hasAuthorship W2783019558A5052060673 @default.
• W2783019558 hasAuthorship W2783019558A5059427438 @default.
• W2783019558 hasAuthorship W2783019558A5062186840 @default.
• W2783019558 hasAuthorship W2783019558A5083717158 @default.
• W2783019558 hasAuthorship W2783019558A5084360444 @default.
• W2783019558 hasAuthorship W2783019558A5090611203 @default.
• W2783019558 hasBestOaLocation W27830195581 @default.
• W2783019558 hasConcept C105639569 @default.
• W2783019558 hasConcept C112705442 @default.
• W2783019558 hasConcept C126322002 @default.
• W2783019558 hasConcept C144133560 @default.
• W2783019558 hasConcept C168563851 @default.
• W2783019558 hasConcept C197934379 @default.
• W2783019558 hasConcept C203092338 @default.
• W2783019558 hasConcept C2779134260 @default.
• W2783019558 hasConcept C2780132546 @default.
• W2783019558 hasConcept C2910001868 @default.
• W2783019558 hasConcept C42404028 @default.
• W2783019558 hasConcept C44249647 @default.
• W2783019558 hasConcept C59491497 @default.
• W2783019558 hasConcept C71924100 @default.
• W2783019558 hasConceptScore W2783019558C105639569 @default.
• W2783019558 hasConceptScore W2783019558C112705442 @default.
• W2783019558 hasConceptScore W2783019558C126322002 @default.
• W2783019558 hasConceptScore W2783019558C144133560 @default.
• W2783019558 hasConceptScore W2783019558C168563851 @default.
• W2783019558 hasConceptScore W2783019558C197934379 @default.
• W2783019558 hasConceptScore W2783019558C203092338 @default.
• W2783019558 hasConceptScore W2783019558C2779134260 @default.
• W2783019558 hasConceptScore W2783019558C2780132546 @default.
• W2783019558 hasConceptScore W2783019558C2910001868 @default.
• W2783019558 hasConceptScore W2783019558C42404028 @default.
• W2783019558 hasConceptScore W2783019558C44249647 @default.

• next